Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state

NCT01090700 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT01090700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01090700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
September 30, 2010
Enrollment
20 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus